ALS drug testing in patient-derived cells provides personalized window into nervous system

Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating the development of effective drugs. Faced with this challenge, a group of researchers from IMDEA Nanociencia Institute (Madrid), the “Margarita Salas” Biological Research Center and the University of Oxford, led by Dr. Valle Palomo has opted for an innovative approach: working directly with human cells from ALS patients.